| Name | Title | Contact Details |
|---|
Mobility Center Of Va is a Richmond, VA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Vital Incite: Population Health Solutions, is a health care consulting firm offering the insight needed to strategically align healthcare resources to meet the needs of employee populations. Data is the driving force behind the Vital Incite Population Health Solution. We use it to: • Identify health risks trends within an employee population. • Understand how employees are accessing healthcare. • Evaluate the effectiveness of health benefit and wellness programs. • Hold ourselves and vendor partners accountable to improve health risks and expenses Our analytics tools turn health care data into actionable intelligence so that employers can make informed decisions about the health and wellness programs they offer to employees. Our analytics tools combine multiple data sources, including: • Claims Data (medical, dental, vision) • Health Risk Assessments • Biometric Data • Vendor Data We use what we learn from the data to develop program objectives, set impact expectations and track the effectiveness of the program. We are focused on the big picture, helping employers manage their health care spend and helping employees improve their health. We don`t try to solve employer problems with our own solutions. We identify which resources are required, assist an employer in choosing the provider of those resources and then continue to monitor the impact of those programs.
Simplexity Health is a Klamath Falls, OR-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
National Family of Local Therapy Providers providing exceptional care & remarkable experiences. #UpstreamFamily Learn more: https://t.co/fpCrnr3vfc…
Kymera is a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body’s own natural protein degradation system. Kymera’s proprietary targeted protein degradation platform, called Pegasus, enables us to discover highly selective small molecule protein degraders with activity against disease-causing proteins throughout the body. We believe that our small molecule protein degraders have significant advantages over existing therapies and allow us to address a large portion of the human genome that was previously intractable with traditional modalities. Kymera focuses on biological pathways that have been clinically validated but where key biological nodes/proteins have not been drugged or have been inadequately drugged. To date, we have utilized our Pegasus platform to design novel protein degraders focused in the areas of immunology-inflammation and oncology, and continue to apply our platform’s capabilities to additional therapeutic areas.